Keith Usiskin

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

Kaj Stenlöf, William T. Cefalu, Kyung‐Ah Kim et al. · Diabetes Obesity and Metabolism · 2012 · 606 citations · Full text

Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

William J. Sandborn, Brian G. Feagan, Geert D’Haens et al. · New England Journal of Medicine · 2021 · 503 citations · Full text

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

J.‐F. Yale, George L. Bakris, Bertrand Cariou et al. · Diabetes Obesity and Metabolism · 2013 · 480 citations · Full text

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

Nelson B. Watts, John P. Bilezikian, Keith Usiskin et al. · The Journal of Clinical Endocrinology & Metabolism · 2015 · 434 citations · Full text

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

Julio Rosenstock, Naresh Aggarwal, David Polidori et al. · Diabetes Care · 2012 · 415 citations · Full text